PEMF for Migraine
& Headache.

June 2026 · 9 min read · Neurological Protocol

Why Migraine Is One of PEMF's Most Important Clinical Opportunities

Migraine affects approximately 1 billion people globally — making it the second most disabling neurological condition in the world. In the Philippines, migraine prevalence is estimated at 8–12% of the adult population, with working-age women (18–50) disproportionately affected. The condition is characterized by recurrent, moderate-to-severe unilateral headache attacks lasting 4–72 hours, frequently accompanied by nausea, photophobia, and phonophobia.

The pharmacological management gap is significant. Triptans and ergotamines are effective for acute attacks but are contraindicated in patients with cardiovascular risk factors — a group with substantial overlap in middle-aged migraine sufferers. Prophylactic medications (topiramate, valproate, beta-blockers) carry side effects that reduce compliance. For refractory migraine — defined as inadequate response to at least two prophylactic agents — drug-free alternatives become medically necessary, not merely preferred.

PEMF is FDA-cleared for migraine with aura. The mechanism of action is distinct from both acute analgesics and pharmacological prophylactics, and the RCT evidence demonstrates persistent effects lasting months beyond the treatment course itself.

How PEMF Acts on Migraine Neurobiology

Migraine originates in cortical spreading depression (CSD) — a slowly propagating wave of neuronal depolarization — followed by trigeminovascular activation, neurogenic inflammation, and central sensitization. PEMF intervenes at multiple nodes in this cascade:

1. Cortical excitability modulation — Low-frequency PEMF (8–10 Hz) stabilizes cortical membrane potentials, raising the threshold for spreading depression initiation. This is the primary prophylactic mechanism.
2. Trigeminal nerve desensitization — PEMF applied to cervical and cranial coils reduces the firing rate of trigeminal ganglion neurons, interrupting the peripheral sensitization loop that drives recurring attacks.
3. Myofascial trigger point resolution — A significant proportion of chronic migraine is perpetuated by active trigger points in the cervical and shoulder musculature. Repetitive peripheral magnetic stimulation (rPMS) applied to these trigger points directly reduces MIDAS disability scores (PMC7136237: MIDAS 29→13 and 31→15 across two treatment groups).
4. Cortisol and stress hormone normalization — PEMF treatment reduces cortisol levels by approximately 28% (PMC9748435), addressing one of the most consistent migraine trigger mechanisms and reducing inter-attack susceptibility.

The Key Clinical Trial: Refractory Migraine RCT

A randomized, single-blind, placebo-controlled, parallel-group study examined PEMF in patients with refractory migraine — defined as inadequate response to conventional pharmacological prophylaxis. PEMF parameters: 10 Hz, 4–5 mT, squared electromagnetic pulses. Treatment course: 2 weeks of active sessions.

Results in the active PEMF group versus placebo:

• Headache days: significantly reduced — P<0.002
• Headache intensity: significantly reduced — P<0.04
• Duration of headache attacks: significantly reduced — P<0.001
• Work-loss hours due to headache: significantly reduced — P<0.03
• Number of medications taken: significantly reduced — P<0.02

Crucially, follow-up assessment at 4–8 months after the treatment course confirmed that improvements in headache days, attack duration, work-loss hours, and medication use were sustained in the active PEMF group. This sustained prophylactic effect — months after the last session — is the defining characteristic that distinguishes PEMF from symptomatic treatments and sets it apart even from most pharmacological prophylactics that require continuous daily dosing.

rPMS for Cervicogenic Migraine and Myofascial Triggers (PMC7136237)

A separate randomized trial examined repetitive peripheral magnetic stimulation (rPMS) applied specifically to myofascial trigger points in the neck and shoulder muscles — the cervicogenic component that perpetuates chronic migraine in a substantial subset of patients. Two active treatment groups demonstrated:

• MIDAS disability score: 29 → 13 (Group A) and 31 → 15 (Group B)
• Significant reductions in headache frequency following trigger point treatment

For Philippine clinics, this is clinically significant: many migraine patients presenting with chronic daily headache have an underlying cervicogenic component from prolonged desk work, poor posture, and BPO shift patterns. PEMF applied to both the cranial (prophylactic) and cervical (myofascial) targets addresses both pathways simultaneously.

Migraine Subtype Treatment Guide

Clinical Protocol for Migraine Prophylaxis

• Coil placement: cervical (C1–C4) for base prophylaxis; occipital/parieto-occipital for aura subtypes; upper trapezius/levator scapulae for myofascial component
• Frequency: 10 Hz, 4–5 mT (matching the validated RCT parameters)
• Session duration: 25–35 minutes
• Treatment frequency: 3 sessions/week for 4 weeks (induction); then 1–2 sessions/week for maintenance
• Induction course: 12 sessions minimum (the validated RCT used 2-week intensive; extending to 4 weeks improves durability)
• Attack window: avoid treatment during an active migraine attack with severe photophobia; treat in the interictal period
• Outcome tracking: headache diary (days/month, intensity, duration, work-loss hours) at baseline, 4 weeks, and 3 months

PEMF vs. Standard Migraine Prophylactics

Contraindications

Absolute: active cardiac pacemaker or cochlear implant, pregnancy, active epilepsy (separate from migraine with aura — assess individually), active malignancy in the head/neck field. Relative: implanted metal in skull or cervical spine (assess field strength and proximity). Note: migraine with aura is a contraindication for estrogen-containing contraceptives and triptans due to stroke risk — PEMF carries no such vascular risk and is specifically FDA-cleared for this indication.

The Philippine Market Opportunity

Migraine is among the least adequately treated neurological conditions in the Philippines. The neurology specialist shortage means most migraine patients are managed by general practitioners with limited access to prophylactic agents. The BPO sector — approximately 1.3 million workers, predominantly female, under shift-work stress — represents a concentrated, high-prevalence migraine population where work-loss reduction is a quantifiable employer benefit. PEMF clinics positioned near BPO hubs (BGC, Ortigas, Cebu IT Park, Clark) have a natural corporate wellness entry point through migraine management programs.

In the 70+ Israeli clinic network (population: 9M) — now expanding to the Philippines — headache and migraine protocols have shown strong patient retention: the durable 4–8 month effect means patients return for maintenance courses rather than a single treatment series, creating recurring revenue per patient.